Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043669 | 0.82 | MEN1 (0.51) | KCNH2MAP3K5BRD4PLK1MEN1 | |
| SCHEMBL13062604 | 0.81 | MEN1 (0.48) | SLC18A2MEN1KMT2AKDM1A | |
| SCHEMBL13322655 | 0.81 | KCNH2 (0.44) | KCNH2MAP3K5MEN1KMT2A | |
| SCHEMBL13322646 | 0.81 | MAP3K5 (0.52) | MAP3K5MEN1KMT2A | |
| SCHEMBL15128183 | 0.80 | MEN1 (0.37) | SLC18A2MEN1KMT2AKDM1A | |
| SCHEMBL13322647 | 0.78 | OPRK1 (0.42) | KCNH2MAP3K5 | |
| SCHEMBL13322649 | 0.78 | MAP3K5 (0.50) | MAP3K5 | |
| SCHEMBL20132959 | 0.72 | VHL (0.43) | KCNH2 | |
| SCHEMBL3965311 | 0.70 | MAOB (0.38) | BRD4MEN1KMT2A | |
| SCHEMBL16519555 | 0.70 | KDM1A (0.39) | SLC18A2MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8318735-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | DAPK2, DAPK1, JAK1 | KCNH2 4229/4885MAP3K5 5/4885BRD4 815/4885 |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | KCNH2 2419/4885MAP3K5 8/4885BRD4 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.